Oral drug delivery remains one of the most important and widely adopted routes of administration in pharmaceutical development. Tablets and capsules continue to offer clear advantages in terms of patient acceptance, convenience, stability, scalability and cost-effective manufacture. Yet the science behind oral dose development has changed significantly. Today’s oral medicines are increasingly expected to do more than deliver an active ingredient in a conventional immediate-release format. They must overcome solubility and bioavailability limitations, support challenging drug substance properties, enable modified or targeted release, align with paediatric and patient-centric needs and transition efficiently from early clinical supply to commercial-scale manufacture

This evolution is being driven by the changing nature of pharmaceutical pipelines. Many contemporary small molecule candidates present formulation challenges, particularly poor aqueous solubility, limited permeability, complex solid-state behaviour or potency-related handling requirements. Poor solubility remains one of the most persistent barriers in drug development, making early understanding of API characteristics essential to maximising solubility, stability and therapeutic impact. At the same time, the industry is seeing increased interest in more complex oral dosage forms, including modified-release systems, paediatric-friendly presentations, liquid-filled capsules, amorphous solid dispersions and other enabling technologies designed to improve in vivo performance.

For drug developers, the key question is no longer simply whether a compound can be made into a tablet or capsule. It is whether the selected formulation and process are sufficiently robust, scalable and clinically appropriate to support the product across its lifecycle. That requires a development strategy that integrates formulation science, material understanding, process engineering, analytical capability and regulatory foresight from the outset.

Oral Delivery Remains Central – But Expectations Are Rising

The continued dominance of oral solid dosage advanced processing technologies and contained high-potency capabilities that enable the efficient manufacture of forms reflects their practical value. They are generally easier for patients to take than injectable therapies, comparatively stable during storage and distribution and suitable for large-scale production. However, the simplicity perceived by patients often masks the complexity involved in development and manufacture. As pipelines have shifted towards more challenging molecules, the oral dosage form has had to become more sophisticated.